Moderna (NASDAQ:MRNA) Trading 8.8% Higher – What’s Next?

Moderna, Inc. (NASDAQ:MRNA) traded up 8.8% on Tuesday . The stock traded as high as $35.00 and last traded at $35.90. 3,115,410 shares traded hands during trading, a decline of 75% from the average session volume of 12,516,600 shares. The stock had previously closed at $32.99.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. JPMorgan Chase & Co. decreased their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Finally, HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Stock Down 6.0 %

The firm has a market capitalization of $12.98 billion, a price-to-earnings ratio of -3.63 and a beta of 1.59. The company’s 50 day moving average price is $38.17 and its 200 day moving average price is $53.20.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last three months. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently modified their holdings of the stock. Forum Financial Management LP acquired a new position in Moderna in the fourth quarter valued at approximately $225,000. Blue Sky Capital Consultants Group Inc. purchased a new position in shares of Moderna during the 4th quarter valued at approximately $606,000. GF Fund Management CO. LTD. acquired a new position in shares of Moderna in the 4th quarter valued at $372,000. Vega Investment Solutions purchased a new stake in Moderna during the fourth quarter worth $45,000. Finally, Alpine Global Management LLC acquired a new stake in Moderna during the fourth quarter valued at $224,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.